Editorial: Agency in denial - Stem cell board lacks money, not issues [California]
By Sacramento Bee,
Sacramento Bee
| 08. 13. 2005
People who suffer a serious medical setback often can't come to grips with it. Paralyzed stroke victims, for instance, sometimes insist they can raise their arms when they can't.
Doctors call this disorder "denial syndrome". California's $3 billion stem cell research institute appears to be afflicted by it.
Lawsuits filed by opponents of embryonic stem cell research have prevented the state from issuing bonds for the Institute for Regenerative Medicine, putting the whole program in limbo. These lawsuits are hugely dispiriting to Californians who support stem cell research, but they are a reality, and they could delay the institute's research grants by one or two years.
Institute leaders need to make the most of this lull by settling issues that will continue to dog the institute over the next decade. Instead, Institute Chairman Robert Klein II continues to toot his horn and cry "full steam ahead!" even as his ship remains tethered to the dock.
The latest exercise in institutional denial came Aug. 3 in San Francisco, where the institute held the first meeting of its grants review committee. The...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...